TY - JOUR
T1 - MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
AU - Elad, Sharon
AU - Cheng, Karis Kin Fong
AU - Lalla, Rajesh V.
AU - Yarom, Noam
AU - Hong, Catherine
AU - Logan, Richard M.
AU - Bowen, Joanne
AU - Gibson, Rachel
AU - Saunders, Deborah P.
AU - Zadik, Yehuda
AU - Ariyawardana, Anura
AU - Correa, Maria Elvira
AU - Ranna, Vinisha
AU - Bossi, Paolo
AU - The Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASC/ISOO)
AU - Arany, Praveen
AU - Al-Azri, Abdul Rahman
AU - Blijlevens, Nicole
AU - Hovan, Allan
AU - Fregnani, Eduardo
AU - Fulton, Janet
AU - Gueiros, Luiz Alcino
AU - Rouleau, Tanya
AU - Coller, Janet K.
AU - Al-Dasooqi, Noor
AU - Wardill, Hannah
AU - Ameringer, Suzanne
AU - Antunes, Héliton Spindola
AU - Bateman, Emma H.
AU - Bektas, Kivanc
AU - Bensadoun, René Jean
AU - Ten Bohmer, K.
AU - Brito-Dellan, Norman
AU - Castillo, Daniel
AU - Chiang, Karen
AU - de Mooij, Charlotte
AU - Eilers, June
AU - Epstein, Joel
AU - Galiti, Dimitra
AU - Fall-Dickson, Jane M.
AU - Gobbo, Margherita
AU - Issa Hazboun, Hanan
AU - Jensen, Siri Beier
AU - Johansen, Jorgen
AU - Joy, Jamie
AU - Joy, K.
AU - Kandwal, Abhishek
AU - Kataoka, Tomoko
AU - Keefe, Dorothy
AU - Loprinzi, Charles L.
AU - Lubart, Rachel
AU - Skripnik Lucas, Anna
AU - Majorana, Alessandra
AU - Mayo, Bronwen
AU - de Mooij, Charlotte
AU - Mori, Takehiko
AU - Nair, Raj G.
AU - Nasr, Narmin
AU - Nicolatou-Galitis, Ourania
AU - Ottaviani, Giulia
AU - Migliorati, Cesar
AU - Pentenero, Monica
AU - Porcello, Lorraine
AU - Peterson, Douglas
AU - Potting, Carin
AU - Raber-Durlacher, Judith
AU - van Sebille, Ysabella Z.A.
AU - Soga, Yoshihiko
AU - Sonis, Stephen
AU - Stringer, Andrea M.
AU - Thorpe, Daniel
AU - Tilly, Vanessa
AU - Tissing, Wim
AU - Toro, Juan J.
AU - Treister, Nathaniel Simon
AU - Vaddi, Anusha
AU - Weikel, Dianna
AU - van de Wetering, Marianne
AU - Zur, Eyal
N1 - This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non- commercial and no modifications or adaptations are made.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis. Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.
AB - Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis. Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.
KW - cancer
KW - gastrointestinal
KW - guidelines
KW - mucositis
KW - Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO)
KW - oral
UR - http://www.scopus.com/inward/record.url?scp=85088579802&partnerID=8YFLogxK
U2 - 10.1002/cncr.33100
DO - 10.1002/cncr.33100
M3 - Article
AN - SCOPUS:85088579802
SN - 0008-543X
VL - 126
SP - 4423
EP - 4431
JO - Cancer
JF - Cancer
IS - 19
ER -
